10-Q quarterly report · filed Oct 29, 2026

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 10-Q Quarterly Report

Short answer

Phathom Pharmaceuticals, Inc. (PHAT) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $85M (up 71.1% year over year) with net income of −$14M.

Q3 2026 key financials · XBRL

Revenue
$85M
+71.1% YoY · +14.1% QoQ
Net income
−$14M
+53.6% YoY · +21.0% QoQ
Operating margin
-0.1%
Gross margin
78.3%
EPS (diluted)
−$0.16
+60.0% YoY · +23.8% QoQ

Source: XBRL data from the Phathom Pharmaceuticals, Inc. (PHAT) Q3 2026 10-Q on SEC EDGAR. USD.

Phathom Pharmaceuticals, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $84.7M, up $35.2M from $49.5M YoY, driven by VOQUEZNA products
  • Gross margin 78.3% vs 87.5% YoY, with cost of revenue $18.4M vs $6.2M
  • Net loss $13.9M vs $30.0M YoY, operating loss $0.1M vs $15.3M
  • Cash $184.6M; nine-month operating cash outflow $15.7M vs $161.8M YoY
  • Outlook: cash and anticipated product revenues sufficient for operations at least twelve months; EoE topline results expected fourth quarter 2026

Risk Factors

  • New litigation risk: BDR challenged FDA’s GAIN Act extension of VOQUEZNA exclusivity through May 3, 2032
  • Regulatory risk: adverse ruling could enable earlier ANDA submissions and generic competition
  • Market risk: earlier generics could materially reduce VOQUEZNA sales, pricing and market share
  • Legal risk: Saba intends to seek consolidation of a related challenge with BDR’s lawsuit
  • Operational risk: litigation and FDA proceedings may be lengthy, costly and distracting to management

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Phathom Pharmaceuticals, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.